Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Prostatic Adenocarcinoma
Phase of Trial: Phase II
Latest Information Update: 04 Jul 2018
At a glance
- Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Prednisone (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 22 Jun 2018 Status changed from not yet recruiting to recruiting.
- 29 May 2018 Planned initiation date changed from 9 May 2018 to 14 Jun 2018.
- 27 Apr 2018 Planned initiation date changed from 1 May 2018 to 9 May 2018.